{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:52:25Z","timestamp":1767768745780,"version":"3.48.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Several clinical trials have explored the efficacy and safety of Poly (ADP-ribose) polymerase (PARP) inhibitors in endometrial cancer (EC). However, evidence supporting PARP inhibitors alone or in combination with other medications in advanced or recurrent EC remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We utilized Cochrane Library, PubMed, Web of Science, and Embase to identify clinical trials that evaluated the efficacy and safety of PARP inhibitors in advanced and recurrent EC. The outcomes analyzed included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events (AEs). We computed hazard ratios (HRs) for PFS and OS, with 95% confidence intervals (CIs) from randomized trials. Subgroup analysis was conducted based on the PARP inhibitor combination therapy strategies (with antiprogrammed death 1 [PD-1]\/antiprogrammed death ligand-1 [PD-L1] inhibitors or antiangiogenic agents).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 12 clinical trials for a total number of 1,594 patients diagnosed with advanced or recurrent EC were included in this meta-analysis. The duration of follow-up time ranged from a median of 7.4 to 31.9 months, and the pooled median PFS was 6.43 months. The results showed that the combination of PARP with PD-L1\/PD-1 inhibitors could significantly prolong PFS versus placebo (hazard ratio [HR] = 0.567; 95% confidence interval [CI] = 0.469\u20130.686;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05). Based on the subgroup analysis, the pooled median PFS was found to be 7.59 months for the combination of PARP with PD-L1\/PD-1 inhibitors. In addition, the pooled median PFS at 6 months was 0.44 based on the analysis of four included studies. In the intention-to-treat population, there was no PFS\/OS difference between PARP inhibitor monotherapy and placebo (PFS: HR = 0.684 [95% CI = 0.334\u20131.398],\n                      <jats:italic>p<\/jats:italic>\n                      &amp;gt; 0.05; OS: HR = 0.787 [95% CI = 0.279\u20132.219],\n                      <jats:italic>p<\/jats:italic>\n                      &amp;gt; 0.05). The ORR was notably elevated in the combined therapy group compared with PARP inhibitor monotherapy (OR = 3.34 [95% CI = 1.095\u201310.165],\n                      <jats:italic>p<\/jats:italic>\n                      = 0.034). The most common AEs included fatigue (226, 54.5%), nausea (219, 52.8%), anemia (219, 52.8%), diarrhea (127, 30.6%), and alopecia (121, 29.2%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of a PARP inhibitor with a PD-L1\/PD-1 inhibitor shows modest activity with substantial toxicity, particularly in heavily pretreated and largely pMMR populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD42024556356.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1659650","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:48:06Z","timestamp":1767768486000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Huanhuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangwei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianxu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41572-021-00324-8","article-title":"Endometrial cancer","volume":"7","author":"Makker","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e002255","DOI":"10.1136\/jitc-2020-002255","article-title":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial","volume":"9","author":"Antill","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01021","article-title":"A phase ib\/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (Study 111\/KEYNOTE-146): long-term efficacy and safety update","volume":"41","author":"Makker","year":"2023","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S221001","article-title":"PARP inhibitors in endometrial cancer: current status and perspectives","volume":"12","author":"Musacchio","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113114","article-title":"Endometrial cancer and BRCA mutations: a systematic review","volume":"11","author":"Gasparri","year":"2022","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.135","article-title":"Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort","volume":"29","author":"Ring","year":"2016","journal-title":"Mod Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00286","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.12.016","article-title":"Angiogenesis in endometrial carcinoma: therapies and biomarkers, current options, and future perspectives","volume":"160","author":"Berger","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1158\/1535-7163.MCT-17-1255","article-title":"Nuclear PTEN localization contributes to DNA damage response in endometrial adenocarcinoma and could have a diagnostic benefit for therapeutic management of the disease","volume":"17","author":"Mukherjee","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.04.016","article-title":"A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium","volume":"166","author":"Jackson","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41467-023-37084-w","article-title":"Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma","volume":"14","author":"Madariaga","year":"2023","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.02.025","article-title":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","volume":"165","author":"Post","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2181","article-title":"Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer","volume":"8","author":"Konstantinopoulos","year":"2022","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35151","article-title":"NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib\/olaparib in women with recurrent, persistent, or metastatic endometrial cancer","volume":"130","author":"Rimel","year":"2024","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1656","article-title":"Phase ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer","volume":"27","author":"Westin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040915","article-title":"Phase 2 trial (POLA study) of lurbinectedin plus olaparib in patients with advanced solid tumors: results of efficacy, tolerability, and the translational study","volume":"14","author":"Poveda","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ygyno.2025.07.008","article-title":"randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer","volume":"200","author":"Corr","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7950","DOI":"10.1038\/s41467-025-62678-x","article-title":"Maintenance olaparib after platinum-based chemotherapy for advanced\/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial","volume":"16","author":"Joly","year":"2025","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/s41467-025-56914-7","article-title":"Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced\/metastatic endometrial cancer: the ENDOLA phase I\/II trial","volume":"16","author":"Piffoux","year":"2025","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472","article-title":"Development of PARP and immune-checkpoint inhibitor combinations","volume":"78","author":"Stewart","year":"2018","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01021","article-title":"Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer","volume":"37","author":"Konstantinopoulos","year":"2019","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003777","article-title":"LBA36 - safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair de-sufficient (dMMR) or proficient (MMRp) endometrial cancer (EC): results from GAR-NET","volume":"10","author":"Oaknin","year":"2020","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1158\/1541-7786.MCR-13-0628","article-title":"Hypoxic stress facilitates acute activation and chronic downregulation of Fanconi Anemia proteins","volume":"12","author":"Scanlon","year":"2014","journal-title":"Mol Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2352","article-title":"Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment","volume":"70","author":"Chan","year":"2010","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020401","article-title":"PD-1 and PD-L1 expression in endometrial cancer: A systematic review of the literature","volume":"14","author":"De Tommasi","year":"2025","journal-title":"J Clin Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1659650\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:48:08Z","timestamp":1767768488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1659650\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2025.1659650"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1659650","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1659650"}}